We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to PDGF
News

Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to PDGF

Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to PDGF
News

Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to PDGF

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to PDGF"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Therapeutics Corp. has announce that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,943,376- entitled, "Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells."

The claims contained within this issued patent cover methods of using PDGF to produce neural progenitor populations which can differentiate into neurons and oligodendrocytes but not astrocytes.

The use of PDGF-enriched progenitor cells can be used to treat or ameliorate neural diseases or conditions associated with neuron or oligodendrocytes loss or dysfunction, such as Stroke, Multiple Sclerosis, Traumatic brain injury, Parkinson's Disease and Alzheimer's Disease.

Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "PDGF derived neurons are a cell type that appear to be well suited for the treatment of Parkinson's Disease and potentially for other chronic neurologic disease's. This issued patent continues to add value to our intellectual property (IP) and demonstrates SCT ongoing commitment to the protection and development of its novel IP in the field of central nervous system disease."

Advertisement